GlassScriptPhysician profile
Kayla Glover
NPI 1376001420
$4,701.23
in general payments reported to CMS, 2019-2025
35 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $928 · 2023: $971 · 2024: $557 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.50 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,013.21 | 2021-2025 | |
| Amgen INC. | $728.48 | 2021-2025 | Krystexxa, Parsabiv, Tavneos |
| Otsuka America Pharmaceutical, INC. | $562.32 | 2021-2025 | Jynarque, Rexulti |
| Astrazeneca Pharmaceuticals LP | $458.67 | 2021-2025 | Farxiga, Breztri |
| Opko Pharmaceuticals, LLC | $268.21 | 2021-2024 | Rayaldee |
| Lilly USA, LLC | $165.15 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $149.79 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $139.25 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $125.28 | 2021-2024 | Injectafer |
| Calliditas Therapeutics US INC. | $112.70 | 2022-2024 | Tarpeyo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.16 | 2025 | Caplyta |
| Abbvie INC. | $94.30 | 2025 | |
| Novo Nordisk INC | $90.38 | 2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $74.72 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.79 | 2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.54 | 2025 | Trintellix |
| Lundbeck LLC | $50.52 | 2025 | Rexulti |
| Akebia Therapeutics INC | $46.54 | 2021-2023 | Auryxia |
| Axsome Therapeutics, INC. | $39.18 | 2025 | Auvelity |
| Pfizer INC. | $38.28 | 2025 | |
| Tolmar, INC. | $35.72 | 2025 | Jatenzo |
| Vifor Pharma, INC. | $30.67 | 2021 | |
| Dexcom, INC. | $29.22 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $28.53 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $25.58 | 2024 | |
| Globus Medical, INC. | $25.44 | 2025 | Senza |
| Antares Pharma, INC. | $21.53 | 2025 | Xyosted |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.25 | 2024 | |
| Corium, LLC | $21.21 | 2025 | Azstarys |
| Fresenius USA Marketing, INC. | $18.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2025 | Xifaxan |
| Arbor Pharmaceuticals, INC. | $14.85 | 2021 | |
| Aurinia Pharma U.S., INC. | $14.84 | 2021 | |
| Exact Sciences Corporation | $14.36 | 2025 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.